Results 281 to 290 of about 268,746 (338)
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. [PDF]
Yau JCW, Chan LL, Chan SL.
europepmc +1 more source
Lei et al. demonstrate that cancer stem cells (CSCs) play a pivotal role in impairing the differentiation of CD103+ T cells in patients with non‐small‐cell lung cancer. The key mechanism involves CSC‐derived acetyl‐CoA, which disrupts CD103+ T cell differentiation by sequentially inducing acetylation and ubiquitination of the Blimp‐1 protein. Targeting
Jiaxin Lei +10 more
wiley +1 more source
Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. [PDF]
Cruz Carreras MT +6 more
europepmc +1 more source
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang +16 more
wiley +1 more source
Immune checkpoint inhibitors against thyroid cancer. [PDF]
Zhao K, Chen L.
europepmc +1 more source
ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment
ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy.
Nuozi Song +12 more
wiley +1 more source
Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach. [PDF]
Casal A +8 more
europepmc +1 more source
This study reveals that photothermal therapy, while inducing immunogenic cell death in triple‐negative breast cancer, paradoxically activates the oncogenic mTOR pathway to drive immune evasion. To counter this, a smart nanocomposite is engineered to co‐deliver localized hyperthermia and mTOR inhibition.
Yujie Zhao +13 more
wiley +1 more source
Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment. [PDF]
Feng Y +11 more
europepmc +1 more source

